• Department of Brest Surgery Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;
LÜQing, Email: lvqingwestchina@163.com
Export PDF Favorites Scan Get Citation

Objective To summarize the progress in mechanisms of resistance to trastuzumab in treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods By searching Pubmed and CNKI, the literatures of mechanisms of resistance to trastuzumab in treating HER2-positive breast cancer were reviewed. Results The possible mechanism of resistance to trastuzumab are thought to include HER2 gene amplification and high protein expression; impaired access of trastuzumab to HER2; bidirectional crosstalk between ER and HER2; HER2 downstream signal transduction pathway activation; expansion expression of other RTKs and membrane-associated receptors; alterations in apoptosis and cell cycle control as well as multi-gene mutation, etc. Conclusions Mechanisms of trastuzumab resistance in HER2-positive breast cancer is complicated, a better understanding will be achieved by comprehensive analysis of existing possible mechanisms. The outcome of HER2-positive breast cancer patients who developed resistance to trastuzumab will be improved by appropriate multi-target regime.

Citation: ZHOU Yu-ting, TAN Qiu-wen, LÜ Qing. Mechanisms of Resistance to Trastuzumab in Treating HER2-Positive Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(10): 1280-1284. doi: 10.7507/1007-9424.20160328 Copy

  • Previous Article

    Research Progress on Related Gene of Stem Cell Therapy for Acute-on-Chronic Liver Failure
  • Next Article

    胸腔镜结扎胸导管治疗右颈淋巴结清扫术后乳糜漏1例报道